Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5005—Wall or coating material
  • A61K9/5021—Organic macromolecular compounds
  • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
  • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
  • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
  • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4833—Encapsulating processes; Filling of capsules
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5005—Wall or coating material
  • A61K9/5021—Organic macromolecular compounds
  • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5005—Wall or coating material
  • A61K9/5021—Organic macromolecular compounds
  • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
  • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5005—Wall or coating material
  • A61K9/5021—Organic macromolecular compounds
  • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
  • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
  • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
  • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids

Definitions

• the present invention aims to provide an oral solid form, on the one hand allowing the immediate release of the active compound it contains in a 0.1N hydrochloric acid solution, representative of a gastric medium, and on the other hand resistant to most grinding modes used to grind the oral solid form to obtain the active compound in the form of a fine powder and to facilitate its diverted use.
• the oral solid forms such as capsules or tablets, have insufficient resistance to the extraction of the active compound that they contain, and can thus be misused.
• the resulting fine powder can be inhaled or dissolved and extracted to prepare an injectable product.
• WO 2007/054378 discloses oral and solid pharmaceutical forms consisting of particles of active compound comprising a modified release coating and resistant to grinding, said particles optionally being associated with a viscosifying agent or a sequestering agent.
• immediate-release formulations of active compound must release the majority of the active compound they contain. contain in a relatively short time.
• the oral solid immediate release form disintegrates very rapidly, so as to release the active compound as quickly as possible.
• US 2006/0078614 provides compositions comprising particles coated by a membrane to mask the taste of the active compound they contain and to quickly release almost all of their contents in the stomach.
• EP 1 491 184 discloses immediate release tablets film-coated with a coating masking the taste of the active ingredient they contain.
• the document US 2012/0093938 details the composition of orodispersible tablets, immediate release of diphenhydramine and its salts, the active particles contained in the tablets being optionally film coated with a coating masking the taste of the asset that they contain.
• US 2012/0082729 discloses an oral form obtained by compression and dissolving rapidly in the mouth, comprising microparticles of active compound that can be coated with a coating masking the taste of the active compound that they contain.
• the present invention solves this problem.
• coated particles containing the active compound and having a specific composition and structure, as described later, are resistant to grinding. They make it possible to access, in a relatively inexpensive and rapid industrial process, oral solid forms resistant to misuse of the active compound which they contain, without affecting the immediate release of said active compound in a hydrochloric acid solution 0, 1N.
• the invention relates to an oral form, especially multiparticulate, immediate release of at least one active compound, comprising coated particles, each of said particles being formed of a non-monocrystalline core containing said compound active,
• said core being coated with at least one coating layer comprising:
• the weight ratio polymer (B) / polymer (A) being between 85/15 and
• said coating layer representing at least 30% by weight of the total weight of said coated particles.
• said core is coated with at least one coating layer comprising: (A) at least 25% by weight of polymer selected from ethylcellulose, cellulose acetate, cellulose acetate butyrate, ammonio (meth) acrylate copolymers, polymers and copolymers of acid esters ( meth) acrylics and mixtures thereof; and
• the weight ratio polymer (B) / polymer (A) being between 75/25 and 50/50.
• the term "ethylcellulose” is understood to mean all ethylcelluloses.
• cellulose acetate includes all cellulose acetates.
• cellulose acetate butyrate covers all cellulose acetobutyrates.
• aminoalkyl methacrylate copolymers or the expression “amino methacrylate copolymers” will be used interchangeably in the description.
• coated particles formed of a non-monocrystalline core containing at least one active compound, said core being coated with at least one coating layer comprising:
• the weight ratio polymer (B) / polymer (A) being between 85/15 and
• said coating layer representing at least 30% by weight of the total weight of said coated particles
• oral form or “oral form, especially multiparticulate” refers to any form consisting of several particles or units containing the active compound, as opposed to monolithic or unit forms consisting of a single unit.
• units or “particles” will be used interchangeably in the following description.
• the particles or units contained in the oral form, in particular multiparticulate are individually coated. They can be microbeads, microspheres, pellets, particles or mini-tablets.
• the oral form, especially multiparticulate, consisting of particles or coated units may be in the form of a tablet, sachet, capsule or any other suitable form.
• the coated particles containing the active compound and constituting the oral form, especially multiparticulate, according to the invention are advantageously resistant to grinding, so that it is very difficult to break their coating and obtain a fine powder of the active compound.
• After grinding the oral form it is thus very difficult to obtain the active compound in the form of fine or finely divided powder, that is to say in the form of crystals or small particles whose average diameter is generally between 5 and 50 ⁇ .
• Such a size of crystals or particles is known to increase the rate of solubilization of the active compound, thus promoting its rapid absorption in the nasal mucosa but also its extraction in order to prepare an injectable product.
• coated particles containing the active compound and constituting the oral form, especially multiparticulate, according to the invention are hereinafter referred to as "coated particles”.
• the coated particles containing the active compound have, after grinding, a variation of the average diameter less than or equal to 20%, preferably less than or equal to 15%, more preferably less than or equal to 10% and more preferably less than or equal to 5% .
• This small diameter variation scale qualifies a grinding resistance of the particles tested.
• grinding-resistant is meant that the population of coated particles containing the active compound has, after grinding according to the procedure described below, a size distribution, such that the difference between the two average diameters, determined by analytical sieving, respectively before grinding (D1) and after grinding (D2), that is to say the variation of the average diameter calculated according to the following formula:
• This grinding resistance of the coated particles is evaluated according to the following protocol, based on the mortar technique and its pestle and implemented in the examples. Grinding test of coated particles
• the grinding test is carried out using an automatic mortar grinder, mortar grinder type RM 200 Retsch company equipped with its stainless steel mortar and stainless steel pestle.
• the pestle is placed in an eccentric horizontal position.
• the vertical position of the pestle is set on the index 8.
• a test portion of 20 g of particles is introduced into the mortar and milled for 1 minute.
• the powder obtained is recovered in its entirety and its average diameter is determined by analytical sieving, as described below.
• This test is representative of the grinding methods usually used by misusers, such as: mortar and pestle, coffee grinder, crushing between two spoons, crunching and chewing, etc.
• the oral form, in particular multiparticulate, according to the invention immediately releases the active compound that it contains.
• immediate release and “for immediate release” qualify the ability of particles or the oral form, especially multiparticulate, to release at least 75% of the active compound in a shorter period or equal to 45 minutes in 0.1N hydrochloric acid solution.
• the amount of active compound released is quantified using Device 2 type dissolution equipment (Paddle Apparatus), in 900 ml of 0.1 N hydrochloric acid solution at 37 ° C. and at a rate of paddle rotation of 100 revolutions / min, according to the method of the European Pharmacopoeia, 7 th Edition 2012 (7.5). Chapter 2.9.3. - Dissolution test of solid forms.
• Device 2 type dissolution equipment Paddle Apparatus
• the coated particles and the oral form release at least 80% of the active compound, in particular at least 90% of the active compound, in a duration less than or equal to 45 minutes, in particular less than or equal to 30 minutes.
• polymers (A) For purposes of simplification of reading, the polymers chosen from the above-mentioned list of polymers (A) will be referred to below as “water-insoluble polymers” or “polymers (A)”; and the polymers chosen in the list of polymers (B) mentioned above under the name “polymers soluble in 0.1N hydrochloric acid solution” or “polymers (B)”.
• polymer is used in the text to denote either a single polymer or a mixture of polymers.
• active compound is intended to denote either a single active compound or a mixture of active compounds.
• coated particles according to the invention comprise a composition and a structure adjusted, on the one hand, to make them resistant to grinding and, on the other hand, to obtain the immediate release of the active compound that they contain.
• coated particles according to the invention are structurally organized into a core containing the active compound and coated or film-coated with a coating.
• the coated particles according to the invention have an average diameter less than or equal to 1000 ⁇ .
• the coated particles have a mean diameter of between 50 and 600 ⁇ , in particular between 100 and 400 ⁇ , more particularly between 150 and 300 ⁇ .
• the average diameter of the coated particles is determined by analytical sieving, in particular using a screen sieve containing a sieve bottom and different sieves with decreasing mesh openings, as more specifically described in the following examples.
• the sieve column more particularly comprises sieves with the following mesh openings: 1000, 710, 500, 250, 100 and 50 ⁇ .
• the average diameter of the coated particles by analytical sieving is calculated according to the following formula:
• the core of the coated particles contains one or more active compounds.
• the core of the coated particles is not monocrystalline.
• non-monocrystalline is meant to exclude, within the meaning of the invention, the cores formed of a single crystal of said active compound.
• coated particles according to the invention are compatible with a large variety of active compounds and are not limited to the use of the active compounds described more particularly subsequently. As is apparent from the examples below, the coated particles according to the invention allow immediate release of the active compound they contain while remaining resistant to grinding through their structural organization and the composition of their coating. These properties are verified with active compounds of different nature, as also demonstrated in the examples.
• the coated particles according to the invention are particularly advantageous for active compounds, in particular pharmaceutical or veterinary compounds, the abuse of which may give rise to addictive behaviors, such as, for example, active compounds classified as psychotropic or narcotic.
• the active compound contained in the coated particles according to the invention may be, for example, chosen from one of the following families of active substances: amphetamines, anorectics, antidepressants, antiepileptics, antiparkinsonians, anxiolytics, barbiturates, benzodiazepines, hypnotics, narcotics, neuroleptics, opioids, psychostimulants and psychotropic drugs.
• the active compound is selected from psychotropic drugs and narcotics, preferably selected from oxybate, its pharmaceutically acceptable salts, polymorphs and solvates, and opioids and opioid analogues, these the last being more particularly chosen from oxycodone, oxymorphone, rhydromorphone, hydrocodone, tramadol, morphine, buprenorphine, dextropropoxyphene, propoxyphene, codeine, fentanyl, alfentanyl, remifentanyl, methadone , pethydine, nalbuphine, levomethadyl acetate, difenoxine, diphenoxylate, loperamide, pentazocine, butorphanol, levorphanol, tapentadol and their pharmaceutically acceptable salts, polymorphs and solvates, more particularly chosen from the group consisting of oxycodone hydrochloride, hydromorphone hydrochloride, oxy
• the active compound is an opioid or an opioid analogue.
• the active compound used may be chosen from oxycodone, oxymorphone, rhydromorphone, hydrocodone, tramadol, morphine, buprenorphine, dextropropoxyphene, propoxyphene, codeine, fentanyl, alfentanyl, remifentanyl, methadone, pethydine, nalbuphine, levomethadyl acetate, difenoxine, diphenoxylate, loperamide, pentazocine, butorphanol, levorphanol, tapentadol and their pharmaceutically acceptable salts, polymorphs and solvates.
• It may be, for example, oxycodone hydrochloride, hydromorphone hydrochloride, oxymorphone hydrochloride or morphine sulfate.
• the active compound is oxybate or its pharmaceutically acceptable salts, polymorphs and solvates.
• the core of the coated particles according to the invention is of compact and globally spherical shape.
• the core of the coated particles according to the invention has an average diameter less than or equal to 450 ⁇ , preferably less than or equal to 300 ⁇ , preferably less than or equal to 250 ⁇ , in particular between 80 and 250 ⁇ .
• the core of the coated particles can be:
• a granule containing the active compound optionally mixed with at least one excipient for example a binding agent, a diluent or a filler, a surfactant, a disintegrant, a buffer agent or an antifoam agent
• a granule consisting of a support particle, also called an inert core covered with a layer comprising the active compound optionally mixed with at least one excipient, for example a binding agent, a diluent or a filler, a surfactant, a disintegrant, a buffering agent or an anti-foam agent.
• the core of the coated particles according to the invention may thus comprise, in addition to the active compound, in particular as described above, at least one binding agent, in particular selected from:
• hydroxypropylcellulose of low molecular weight such as Klucel ® EF from Aqualon-Hercules
• hydroxypropylmethylcellulose (or hypromellose) of low molecular weight such as Methocel ® E3 or Dow E5
• low molecular weight methylcellulose such as Methocel ® Al 5 from Dow
• polyvinylpyrrolidone (or povidone) low molecular weight e.g. Plasdone ® K29 / 32 from ISP or Kollidon ® 30, BASF
• copolymer of vinyl pyrrolidone and vinyl acetate e.g. Plasdone ® S630 from ISP or Kollidon ® VA 64 from BASF
• Plasdone ® S630 from ISP or Kollidon ® VA 64 from BASF
• the low molecular weight hydroxypropylcellulose corresponds to hydroxypropylcellulose grades with a molar mass of less than 800,000 g / mol, preferably less than or equal to 400,000 g / mol and in particular less than or equal to 100,000 g / mol.
• the hydroxypropylmethylcellulose (or hypromellose) of low molecular weight corresponds to the hydroxypropylmethylcellulose grades whose viscosity of a 2% solution in water at 20 ° C. is less than 1000 mPa.s, preferably less than or equal to 100 mPa.s and in particular less than or equal to 15 mPa.s.
• the low molecular weight methylcellulose corresponds to the grades of methylcellulose whose viscosity of a 2% solution in water at 20 ° C is less than 1000 mPa.s, preferably less than or equal to 15 mPa.s.
• the polyvinylpyrrolidone (or povidone) of low molecular weight corresponds to the polyvinylpyrrolidone grades of molar mass less than or equal to 1,000,000 g / mol, preferably less than or equal to 800,000 g / mol and particularly less than or equal to 100,000 g / mol. mol.
• the binder is selected from polyvinylpyrrolidone (also known as povidone) low molecular weight (e.g. Plasdone ® K29 / 32 from ISP), hydroxypropylcellulose of low molecular weight (e.g., Klucel ® EF d 'Aqualon-Hercules), hydroxypropylmethyl cellulose (also known as hypromellose) low molecular weight (e.g., Methocel ® E3 or E5 Dow) and mixtures thereof.
• polyvinylpyrrolidone also known as povidone
• povidone polyvinylpyrrolidone
• hydroxypropylcellulose of low molecular weight e.g., Klucel ® EF d 'Aqualon-Hercules
• hydroxypropylmethyl cellulose also known as hypromellose low molecular weight
• the surfactant that may be present, as described above, in the core of the particles according to the invention may be chosen from phospholipids, polysorbates, polyoxyethylene stearates and fatty acid esters derived from sorbitol. polyoxyethylenated, polyoxyethylenated hydrogenated castor oils, polyoxyethylenated alkyl ethers, glycerol monooleate, and mixtures thereof.
• the diluent or filler may be present, as described above, in the heart of the particles according to the invention may be selected from lactose, the sucrose, mannitol (e.g. grades of Pearlitol ® Roquette and especially Pearlitol® SD200), xylitol, erythritol, sorbitols, microcrystalline cellulose (e.g. Avicel ® products from FMC Biopolymer), calcium carbonates (eg Omyapure 35 from Omya), di- and tricalcium phosphates (e.g. Dicafos ® and Tricafos ® from Budenheim), magnesium oxide, talc, magnesium silicate and mixtures thereof.
• lactose the sucrose, mannitol (e.g. grades of Pearlitol ® Roquette and especially Pearlitol® SD200), xylitol, erythritol, sorbitols, microcrystalline cellulose (e.g. Avicel
• the disintegrant may be present, as described above, in the heart of the particles according to the invention may be selected from starches and pregelatinized starches, carboxymethylcellulose, croscarmellose, crospovidone (e.g., Polyplasdone ® grades of ISP, the Kollidon ® CL from BASF), low substituted hydroxypropylcellulose, and mixtures thereof.
• starches and pregelatinized starches carboxymethylcellulose, croscarmellose, crospovidone (e.g., Polyplasdone ® grades of ISP, the Kollidon ® CL from BASF), low substituted hydroxypropylcellulose, and mixtures thereof.
• the buffering agent which may be present, as described above, in the core of the particles according to the invention may be chosen from citric acid, tartaric acid, adipic acid, boric acid and malic acid.
• the anti-foam agent optionally present, as described above, in the core of the particles according to the invention may be chosen from simethicone, dimethicone.
• the core of the coated particles is formed of a support particle, or inert core, covered with a layer comprising at least the active compound (s).
• Said carrier particles may be:
• sucrose e.g. Compressuc ® PS Tereos
• microcrystalline cellulose such as example Avicel ® from FMC Biopolymer, Cellet ® from Pharmatrans or Celphere ® from Asahi Kasei
• sodium chloride such as Omy apure ® 35 from Omya
• calcium carbonate such as Omy apure ® 35 from Omya
• sodium hydrogencarbonate dicalcium phosphate (such as Dicafos ® AC 92-12 from Budenheim) or tricalcium phosphate (eg Tricafos ®
• the carrier particles can also be any other excipient particles (s) pharmaceutically acceptable (s) such as hydroxypropyl cellulose particles (e.g. Klucel ® from Hercules Aqualon), guar gum particles (e.g. Grinsted ® Guar from Danisco), xanthan particles (such as Xantural ® 180 from CPKelco).
• excipient particles e.g. Klucel ® from Hercules Aqualon
• guar gum particles e.g. Grinsted ® Guar from Danisco
• xanthan particles such as Xantural ® 180 from CPKelco.
• the carrier particles are sugar spheres or microcrystalline cellulose spheres, Cellets such as ® 90, Cellets 100 ® or Cellets ® 127 marketed by Pharmatrans or all spheres sugar or microcrystalline cellulose with a mean diameter by volume equal for example to about 95 ⁇ , 170 ⁇ or 140 ⁇ , or Celphere ® CP 203, Celphere ® SCP 100 and more particularly the fraction of Celphere ® SCP 100 less than 100 ⁇ , marketed by Asai Kasei, or all spheres of microcrystalline cellulose with a mean diameter by volume equal for example to about 230 ⁇ , 100 ⁇ , or particles of dicalcium phosphate, for example Dicafos ® AC 92-12 and more particularly the fraction of Dicafos ® AC 92-12 between 50 and 100 ⁇ or any particles of dicalcium phosphate with a mean diameter by volume of 75 ⁇ .
• Cellets such as ® 90, Cellets 100 ® or Cellets ® 127 marketed by
• the active layer covering the support particle to form the core of the coated particles of the invention comprises, in addition to the active compound, at least one binding agent.
• the layer containing at least said active compound and covering the support particle, or inert core may represent at least 10% by weight, preferably at least 20% by weight, preferably at least 30% by weight, preferably at least 50% by weight, preferably at least 60% by weight, more preferably from 70 to 95% by weight and in particular from 80 to 90% by weight by weight of the total weight of the core of the coated particle.
• the core of the coated particles, containing the active compound is covered with a coating whose composition and thickness are precisely adjusted to, on the one hand, provide the immediate release of said active compound and on the other hand, contribute to making the coated particles resistant to grinding according to the grinding test described above.
• the coating layer also called coating or film coating, which covers the core of the coated particles represents at least 30% by weight of the total weight of the coated particles; in other words, the coated particles have an average coating weight ratio of at least 30%.
• the coating may represent from 30 to 60% by weight, in particular from 30 to 55% by weight and more particularly from 30 to 50% by weight of the total weight of the coated particles.
• the coating layer comprises:
• the coating layer comprises:
• the weight ratio between the soluble polymer in a solution of 0.1 N hydrochloric acid and the water-insoluble polymer is between 85/15 and 50/50, preferably between 75/25 and 50/50, preferably between 70/30 and 50/50 and preferably between 60/40 and 50/50.
• the water insoluble polymer is selected from ethylcellulose,
• the water-insoluble polymer is chosen from ethylcellulose, cellulose acetate and ammonio (meth) acrylate copolymers.
• water insoluble polymers used according to the invention can be cited: ethylcellulose, especially marketed under the name Ethocel ® by Colorcon, and more particularly Ethocel ® grade 20; cellulose acetate, sold in particular under the name CA 398-ONF by Eastman; cellulose acetate butyrate, especially marketed under the name CAB 171-15 by Eastman; copolymers of ammonio (meth) acrylate, especially those marketed under the names Eudragit ® RL and Eudragit ® RS by Evonik; polymers and copolymers of esters of (meth) acrylates, in particular those sold under the Eudragit ® NE and EUDRAGIT ® NM denominations.
• the water-insoluble polymer is present in a content of between 15 and 60% by weight, preferably between 25 and 50% by weight, in particular between 25 and 45% by weight, relative to the total weight of said coating layer.
• the coating layer may comprise from 30 to 45% by weight of water insoluble polymer.
• the polymer soluble in a solution of 0.1N hydrochloric acid is chosen from:
• PVP polyvinylpyrrolidone
• hydroxypropylmethylcellulose (or hypromellose or HPMC) of low molecular weight
• HPMC hydroxypropylcellulose
• HPC hydroxypropylcellulose
• methylcellulose of low molecular weight hydroxyethylcellulose of low molecular weight
• hydroxyethylmethylcellulose maltodextrin
• poloxamers which are triblock copolymers of ethylene oxide, propylene oxide and ethylene oxide;
• polyethylene glycols with a molar mass of between 3,000 and 20,000 g / mol;
• copolymers of methyl vinyl ether and of maleic anhydride or of maleic acid copolymers of aminoalkyl methacrylate, in particular copolymers of butyl methacrylate, 2-dimethylaminoethyl methacrylate and methyl methacrylate 1/2/1;
• the polyvinylpyrrolidone (or povidone) of low molecular weight corresponds to the polyvinylpyrrolidone grades of molar mass less than or equal to 1,000,000 g / mol, preferably less than or equal to 800,000 g / mol and particularly less than or equal to 100,000 g / mol. mol.
• the hydroxypropylmethylcellulose (or hypromellose) of low molecular weight corresponds to the hydroxypropylmethylcellulose grades whose viscosity of a 2% solution in water at 20 ° C. is less than 1000 mPa.s, preferably less than or equal to 100 mPa.s and in particular less than or equal to 15 mPa.s.
• the low molecular weight hydroxypropylcellulose corresponds to hydroxypropylcellulose grades with a molar mass of less than 800,000 g / mol, preferably less than or equal to 400,000 g / mol and in particular less than or equal to 100,000 g / mol.
• the low molecular weight methylcellulose corresponds to the grades of methylcellulose whose viscosity of a 2% solution in water at 20 ° C is less than 1000 mPa.s, preferably less than or equal to 15 mPa.s.
• the low molecular weight hydroxyethylcellulose corresponds to a hydroxyethylcellulose whose viscosity of a 2% solution in water at 25 ° C is less than 1000 mPa.s.
• the polymer soluble in 0.1 N hydrochloric acid solution is chosen from low molecular weight polyvinylpyrrolidone, low molecular weight hydroxypropylmethylcellulose, low molecular weight hydroxypropylcellulose and copolymers of butyl methacrylate, 2-dimethylaminoethyl methacrylate and methyl methacrylate 1/2/1.
• polymers soluble in a 0.1N hydrochloric acid solution which can be used according to the invention, mention may be made of copolymers of butyl methacrylate, 2-dimethylaminoethyl methacrylate and methyl methacrylate 1/2/1 for example marketed under the name Eudragit ® E by the company Evonik, and in particular the grades Eudragit ® El 00 and Eudragit ® EPO; polyvinylpyrrolidone, also known as povidone, low molecular weight, for example marketed under the trade name Plasdone ® by ISP, especially the rank Plasdone ® K29 / 32; hydroxypropyl methylcellulose also called hypromellose, low molecular weight, for example marketed under the trade name Methocel ® by Colorcon and more particularly Methocel ® grade E3; polyvinyl acetate diethyl aminoacetate, e.g. sold under the name AEA ® by Sanlky
• the polymer soluble in a 0.1N hydrochloric acid solution as defined above is present in a content of between 40 and 85% by weight, preferably 40 and 75% by weight, and preferably still between 45 and 60% by weight relative to the total weight of said coating layer.
• the coating of the coated particles according to the invention may further comprise at least one plasticizer.
• plasticizer is meant indifferently denotes a single plasticizer or a mixture of plasticizers.
• the plasticizing agent may in particular be chosen from:
• glycerol and its esters and preferably from acetylated glycerides, glyceryl mono-stearate, glyceryl triacetate, glyceryl tributrate,
• phthalates and preferably from dibutyl phthalate, diethyl phthalate, dimethyl phthalate, dioctyl phthalate,
• citrates and preferably from acetyltributyl citrate, acetyltriethyl citrate, tributylcitrate, triethylcitrate,
• sebacates and preferably from diethylsébaçate, dibutylsébaçate, adipates,
• polyethylene glycols of molar mass less than or equal to
• fumarates preferably diethylfumarate
• malates preferably diethyl malate
• oxalates preferably diethyloxalate
• succinates preferably the dibutylsuccinate
• malonates preferably diethyl malonate
• the plasticizing agent is more particularly chosen from triethyl citrate and polyethylene glycols with a molar mass of less than or equal to 3,000 g / mol.
• the plasticizing agent is present at a content less than or equal to
• the polymer soluble in a 0.1N hydrochloric acid solution according to the invention, the water-insoluble polymer and the plasticizing agent represent at least 70% by weight, in particular at least 80% by weight and more particularly at least 90% by weight of the total weight of the coating layer.
• water-insoluble polymer chosen from ethylcellulose or cellulose acetate
• plasticizer chosen from triethyl citrate and polyethylene glycol of molar mass of about 400 g / mol.
• the coating of the coated particles represents between 40 and 55% by weight of the total weight of the coated particles and comprises:
• the coating of the coated particles represents between 40 and 55% by weight of the total weight of the coated particles and comprises:
• the coating comprises at most 30% by weight of filler, in particular less than 20% by weight, preferably less than 10% by weight filler, relative to the total weight of said coating, or even totally free of charge.
• the filler may be talc.
• the coating may comprise various other additional adjuvants conventionally used in the field of coating. It can be, for example:
• pigments and dyes such as, for example, titanium dioxide, calcium sulphate, calcium carbonate, iron oxides, natural or synthetic food dyes;
• anti-foam agents such as, for example, simethicone, dimethicone
• surfactants such as, for example, phospholipids, polysorbates, polyoxyethylene stearates, polyoxyethylenated fatty acid and sorbitol esters, polyoxyethylenated hydrogenated castor oils, polyoxyethylenated alkyl ethers, glycerol monooleate, and their mixtures.
• the coating of the particles according to the invention does not contain any active compound.
• the coating layer does not comprise other compounds than the abovementioned polymers and the possible plasticizer (s) (s).
• the coating of the coated particles according to the invention may consist of a single coating layer or of several coating layers formed in successive steps. According to a particularly preferred embodiment, it is composed of a single coating layer as described above.
• the particles, the structure and composition of the coating are not in accordance with the invention, are not resistant to grinding to the scale required according to the invention as previously exposed and / or do not allow immediate release active compound contained in said coated particles and / or are not prepared in an economical and fast process.
• the core of the coated particles of the invention can be obtained according to several techniques such as for example:
• agglomeration of the active compound preferably sprayed in the molten state such as, for example, according to the Glatt ProCell TM technique; or
• spheronization of the active compound with optionally one or more excipient (s) physiologically acceptable (s), the spheronization being carried out for example in a fluidized air bed apparatus equipped with a rotor, in particular according to the CPS TM technique of Glatt; or
• the active compound for example in a fluidized air bed apparatus optionally equipped with a Wiirster tube, the active compound, optionally with one or more physiologically acceptable excipient (s), in dispersion or in solution in an aqueous solvent or organic on a support particle.
• physiologically acceptable excipient s
• the coating layer of the coated particles is obtained by spraying, in particular in a fluidized air bed apparatus, a solution, suspension or dispersion comprising at least one polymer (A) insoluble in water as defined above, at least one polymer (B) soluble in a 0.1N hydrochloric acid solution as defined above, and optionally at least one plasticizing agent, on the cores comprising the active compound, in particular the cores described above and obtained by the application on a support particle, or inert core, of a layer containing at least said active compound.
• a solution, suspension or dispersion comprising at least one polymer (A) insoluble in water as defined above, at least one polymer (B) soluble in a 0.1N hydrochloric acid solution as defined above, and optionally at least one plasticizing agent, on the cores comprising the active compound, in particular the cores described above and obtained by the application on a support particle, or inert core, of a layer containing at least said active compound.
• the coating is formed by spraying in a fluidized air bed apparatus equipped with a Wiirster and in a bottom spray orientation.
• Said solution, suspension or coating dispersion comprises water, one or more organic solvents, or mixtures thereof.
• the organic solvent is selected from solvents known to those skilled in the art.
• the solvent of the solution, suspension or coating dispersion comprises less than 40% by weight, in particular less than 30% by weight, especially less than 20% by weight, preferably less than 10% by weight. by weight of water, relative to the total weight of said solvent.
• acetone / isopropanol mixture 60/40 m / m
• an acetone / water mixture 90/10 m / m
• an ethanol / water mixture 70/30.
• the polymers and, where appropriate, the plasticizer and the filler are sprayed in the form of a solute, that is to say in a form solubilized in a solvent to promote the homogeneity of the coating formed. .
• the solution, suspension or coating dispersion is free of charge.
• the present invention further relates to the use of such coated particles for the preparation of an immediate-release oral form of an active compound
• the use of such coated particles is particularly advantageous for active compounds likely to be diverted from their normal use, in particular psychotropic drugs and narcotics, and more particularly chosen from the active compounds described above.
• the active compound is chosen from opioids and more particularly from oxycodone, oxymorphone, hydromorphone, hydrocodone, tramadol, morphine and their pharmaceutically acceptable salts or hydrates.
• the oral form, especially multiparticulate, according to the invention may comprise, in addition to the coated particles immediate release of active compound according to the invention, at least one viscosifying agent.
• the viscosifying agent is more particularly intended, when the oral form, especially multiparticulate, intact or milled, is introduced into a small volume of injectable solvent, especially in a volume less than or equal to 10 ml, to transform the corresponding mixture into a inhomogeneous paste, too viscous to be filtered or injected through a needle of gauge 25 or greater, for example gauge 25, 26, 27, 29, 30 or 31, thereby preventing the production of an injectable liquid containing the active compound under form immediately available.
• An oral form, in particular multiparticulate, according to the invention may therefore comprise at least one viscosifying agent distinct from the coated particles comprising the active compound.
• the viscosifying agent included in the oral form, especially multiparticulate, according to the invention is entirely separate from the coated particles comprising the active compound.
• the viscosifying agent is chosen from viscosifiers which are soluble in at least one of the solvents chosen from water, alcohols, ketones and their mixtures.
• the viscosifying agent is capable of increasing the viscosity of a small volume (between 2.5 ml and 10 ml) of solvent, so as to prevent injection, especially intravenously.
• the viscosity becomes so high that the withdrawal of the mixture formed by the introduction of the oral form according to the invention in a small volume of injectable solvent by a syringe becomes impossible.
• an oral form according to the invention may advantageously comprise a mixture of several viscosifiers which will be effective both in the case of extraction in aqueous phase and in an organic solvent.
• the viscosifying agent contributes to preventing the misuse of the oral form by inhalation because it is capable of forming a gel in contact with the nasal mucosa, which gel will interfere with the diffusion of the active compound towards the mucous membranes and thus its absorption.
• the amount of viscosity agent it is readily determinable by those skilled in the art. This amount advantageously corresponds to the minimum amount necessary to make the viscosity of 2.5 mL of extraction liquid at a value greater than or equal to 100 mPa.s, preferably 200 mPa.s, and even more preferably beyond 500 mPa.s, and more preferably 1000 mPa.s.
• the oral form according to the invention comprises up to 500 mg of viscosifying agent.
• the oral form according to the invention comprises between 5 and 500 mg, preferably between 10 and 250 mg, preferably between 10 and
• viscosifying agent 100 mg, more preferably between 10 and 80 mg and in particular between 15 and 60 mg of viscosifying agent.
• the viscosifying agent is chosen from: polyacrylic acids, in particular carbomers, for example
• polyalkylene glycols for example polyethylene glycols with a molar mass greater than or equal to 20 000 g / mol
• alkylene polyoxides for example polyoxides of ethylene or polyoxyethylenes
• polysaccharides preferably chosen from sodium alginate, pectins, guar gum, xanthans, carrageenans, gellanes, hydroxypropylcellulose of high molar mass, hydroxypropylmethylcellulose of high molar mass, methylcellulose of high molar mass, hydroxyethylcellulose of high molar mass and carboxymethylcellulose,
• the high molecular weight polyvinylpyrrolidone corresponds to polyvinylpyrrolidone grades with a molar mass greater than 1,000,000 g / mol.
• the hydroxypropylcellulose of high molar mass corresponds to hydroxypropylcellulose grades with a molar mass greater than or equal to 800 000 g / mol and preferably greater than or equal to 1 000 000 g / mol.
• the hydroxypropylmethylcellulose of high molar mass corresponds to the hydroxypropylmethylcellulose grades whose viscosity of a 2% solution in water at 20 ° C. is greater than or equal to 1000 mPa.s, preferably greater than or equal to 15,000. mPa.s and in particular less than or equal to 100,000 mPa.s.
• the high molecular weight methylcellulose corresponds to the grades of methylcellulose whose viscosity of a 2% solution in water at 20 ° C is greater than or equal to 1000 mPa.s.
• the hydroxyethylcellulose of high molar mass corresponds to a hydroxyethylcellulose whose viscosity of a 2% solution in water at 25 ° C is greater than or equal to 1000 mPa.s.
• the viscosifying agent is a polyoxyethylene, in particular a polyoxyethylene having a high molecular weight, and more particularly a polyoxyethylene having a mean molecular weight of between about 1 million g / mol and about 8 million g / mol. mol.
• For viscosifier include in particular polyoxyethylene marketed by Dow under the reference Sentry Polyox WSR ® 303.
• the oral form according to the invention comprises between 5 and 500 mg, preferably between 10 and 250 mg, preferably between 10 and 100 mg, more preferably between 10 and 80 mg and especially between 15 and 60 mg of polyoxyethylene, in particular polyoxyethylene having a high molecular weight.
• the viscosifying agent for example high molecular weight polyoxethylene, is in the form of particles, distinct from the coated particles with immediate release of active compound according to the invention as described above.
• the particles of viscosifying agent have a size distribution close to that of the coated particles with immediate release of active compound according to the invention, so that they are not separable by sieving the coated particles comprising the active compound.
• the mean volume diameter of the viscosifying agent particles is between 0.5 and 2 times, preferably between 0.7 and 1.5 times, more preferably between 0.8 and 1.5 times, 1.25 times the average diameter by volume of the coated particles with immediate release of active compound.
• an oral form according to the invention is an oral solid form of tablet, capsule or sachet type.
• the oral form, containing the coated particles with immediate release of active compound also comprises one or more physiologically acceptable excipients, commonly used to formulate tablets, capsules or sachets.
• an oral solid form, of capsule or sachet type may contain, besides the coated particles with immediate release of active compound:
• diluents such as lactose, sucrose, sugar spheres (for example P Pharm's Suglets), microcrystalline cellulose (for example Avicel ® from FMC Biopolymer or Cellet ® from Pharmatrans or Celphere ® from Asai Kasei), calcium carbonates (eg Omyapure ® 35 from Omya, Destab ® 90 S Ultra 250 from Particle Dynamics or Hubercal ® CCG4100 from Huber), di- and tricalcium phosphates (eg Dicafos ® and Tricafos ® from Budenheim), magnesium oxide, phosphate and calcium sulphate; lubricants or flow agents such as stearates, in particular magnesium stearate, calcium stearate or zinc stearate, stearic acid, glycerol behenate, sodium stearyl fumarate, talc, colloidal silica;
• stearates in particular magnesium stearate, calcium stearate
• disintegrating agents such as starches and pregelatinized starches (e.g. corn starch), carboxymethylcellulose, croscarmellose, crospovidone (e.g., Polyplasdone ® grades from ISP, Kollidon ® CL from BASF), the low substituted hydroxypropylcellulose;
• dyes or pigments such as titanium dioxide, calcium sulphate, precipitated calcium carbonate, iron oxides, natural food dyes such as caramels, carotenoids, carmine, chlorophyllins, Rocou (or annatto) ), xanthophylls, anthocyanins, betanin, aluminum, and synthetic food dyes;
• aromas for example strawberry, orange, banana, mint
• preservatives such as parabens, in particular methylparaben, ethylparaben, propylparaben and butylparaben, benzoic acid and its salts (for example sodium benzoate), chlorocresol, sorbic acid and its salts, glycerin;
• a solid form according to the invention of the capsule type may in particular comprise at least one diluent with a content of between 0 and 80% by weight, in particular between 0.5 and 50% by weight, and more particularly between 1 and 30% by weight relative to the total weight of the contents of the capsule.
• a solid form according to the invention of the capsule type may comprise at least one lubricant or flow agent at a content of between 0.1 and 5% by weight, in particular between 0.5 and 2% by weight relative to the total weight of the contents of the capsule.
• a solid form according to the capsule-type invention comprises, in addition to the coated particles defined above, at least one diluent, in particular microcrystalline cellulose, and at least one lubricant or flow agent. , in particular selected from magnesium stearate, colloidal silica and mixtures thereof. In particular, these different excipients are used in contents as defined above.
• a compressed solid oral form may contain, in addition to the coated particles with immediate release of active compound:
• diluents or tableting agents such as lactose, sucrose, mannitol (e.g. grades of Pearlitol ® Roquette and particularly Pearlitol ® SD200), xylitol, erythritol, sorbitols, microcrystalline cellulose (for example Avicel ® from FMC Biopolymer or Cellet ® from Pharmatrans or Celphere ® from Asai Kasei), calcium carbonates (for example Omyapure ® 35 from Omya, Destab ® 90 S Ultra 250 from Particle Dynamics or 'Hubercal ® CCG4100 Huber), di- and tri-calcium phosphates (eg Dicafos ® and Tricafos ® Budenheim), magnesium oxide;
• lactose sucrose
• mannitol e.g. grades of Pearlitol ® Roquette and particularly Pearlitol ® SD200
• xylitol erythritol
• lubricants or flow agents such as stearates, in particular magnesium stearate, calcium stearate or zinc stearate, stearic acid, glycerol behenate, sodium stearyl fumarate, talc, colloidal silica, ;
• binding agents such as hydroxyethylcellulose, ethylcellulose, hydroxypropyl cellulose (e.g. Klucel ® Aqualon-Hercules), hydroxypropylmethylcellulose (or hypromellose, e.g. Methocel ® E or K, particularly Methocel ® K15M Dow), methylcellulose (e.g. Methocel ® Al 5 Dow), polyvinyl pyrrolidone (povidone or, e.g.
• Plasdone ® K29 / 32 from ISP, Kollidon ® 30, BASF copolymers of vinylpyrrolidone and 'vinyl acetate (or copovidone, such as Plasdone ® S630 ISP, Kollidon ® VA 64 from BASF), polyethylene oxide, polyalkylenes such as polyethylene glycol, dextrose, the pregelatinized starches, maltodextrins, polyvinyl alcohol, glycerol palmitostearate;
• disintegrants such as pregelatinized starches and starches (eg cornstarch), carboxymethylcellulose, croscarmellose, crospovidone (eg Polyplasdone ® grades of ISP, Kollidon ® CL from BASF), low substituted hydroxypropylcellulose ; dyes or pigments, such as titanium dioxide, calcium sulphate, precipitated calcium carbonate, iron oxides, natural food dyes such as caramels, carotenoids, carmine, chlorophyllins, Rocou (or annatto) ), xanthophylls, anthocyanins, betanin, aluminum, and synthetic food dyes;
• pregelatinized starches and starches eg cornstarch
• carboxymethylcellulose croscarmellose
• crospovidone eg Polyplasdone ® grades of ISP, Kollidon ® CL from BASF
• low substituted hydroxypropylcellulose e.g Polyplasdone ® grades of ISP, Kollidon
• aromas for example strawberry, orange, banana, mint
• preservatives such as parabens, in particular methylparaben, ethylparaben, propylparaben and butylparaben, benzoic acid and its salts (for example sodium benzoate), chlorocresol, sorbic acid and its salts, glycerin;
• a solid form according to the invention of compressed type may in particular comprise at least one compression agent or diluent with a content of between 10 and 80% by weight, in particular between 30 and 75% by weight, and more particularly between 35 and 65% by weight relative to the total weight of the solid form.
• a solid form according to the invention of compressed type may comprise at least one lubricant or flow agent in a content of between 0.1 and 5% by weight, in particular between 0.5 and 2% by weight relative to the weight. total of the solid form.
• the content of binding agent in a solid form according to the invention of compressed type is less than or equal to 40% by weight, in particular less than or equal to 30% by weight, and more particularly between 5 and 20% by weight relative to the total weight of the solid form.
• a solid form according to the invention of compressed type comprises, besides the coated particles, at least one compression agent or diluent, in particular chosen from microcrystalline cellulose, mannitol and their mixtures, and at least a lubricant or flow agent, in particular chosen from magnesium stearate and colloidal silica, and mixtures thereof, and optionally at least one binding agent, especially chosen from hydroxypropylmethylcellulose and methylcellulose.
• an oral form according to the invention is preferably a tablet, a sachet or a capsule.
• the coated particles with immediate release of active compound are premixed with excipients known to those skilled in the art as diluents, lubricants or flow agents, etc. as previously described; the mixture is then divided into capsules or sachet.
• excipients known to those skilled in the art as diluents, lubricants or flow agents, etc. as previously described; the mixture is then divided into capsules or sachet.
• a sequential filling mode of the components one after the other or partially or totally mixed between them can be implemented.
• the coated particles with immediate release of active compound are premixed with excipients known to those skilled in the art such as lubricants or flow agents, diluents or compressive agents, etc. as previously described; the mixture is then compressed.
• Compression can be achieved by any conventional method and its implementation is clearly within the skill of those skilled in the art.
• the tablets advantageously have a significant resistance to rupture.
• the hardness of the tablet can vary from 50 to 500 N, in particular from 60 to 200 N. This hardness can be measured according to the protocol described in the European Pharmacopoeia 7 th edition 2012 ( 7.5) Chapter 2.9.8. : "Resistance to breaking tablets”.
• a solid form according to the invention in particular of the tablet or capsule type, exhibits a level of charge in coated particles with immediate release of active compound of between 5 and 95% by weight relative to its total weight. in particular between 10 and 90% by weight, and more particularly between 20 and 85% by weight.
• oxycodone hydrochloride 1615.0 g of oxycodone hydrochloride and 85.0 g of polyvinylpyrrolidone (also known as povidone; Plasdone ® K29 / 32 from ISP) were introduced under agitation in a reactor comprising 2052.1 g of water and 1105.0 g ethanol. The solution is heated to 65 ° C. When oxycodone hydrochloride crystals and the polyvinylpyrrolidone are dissolved, the solution is sprayed wholly on 300.0 g of cellulose spheres (Cellet ® Pharmatrans 90) in an apparatus with fluidized air bed GPCGl. l in a bottom spray configuration. After spraying, the product obtained is screened on sieves of 80 ⁇ and 250 ⁇ and the product fractions smaller than 80 ⁇ and greater than 250 ⁇ are removed. 2052, 1 g of granules are then recovered.
• polyvinylpyrrolidone also known as povidone; Plas
• 300.0 g of granules obtained according to the preceding step are coated at room temperature in a GPCG1 fluidized air bed apparatus.
• l equipped with a Wiirster tube with 135.0 g of a copolymer of butyl methacrylate, 2-dimethylaminoethyl methacrylate and methyl methacrylate (Eudragit ® E100 from Evonik), 135.0 g of cellulose acetate (CA 398-10 F from Eastman) and 30.0 g of triethyl citrate (Citrofol AI from Jungbunzlauer) dissolved in a mixture of 3105 g of acetone and 345 g of water (90/10 m / m). Spraying is carried out with a flow rate of the liquid to be sprayed at 18 g / min.
• coated particles prepared as described above are milled for 1 minute using an RM 200 mortar grinder from Retsch, according to the previously described protocol.
• All of the powder is recovered and sieved on a sieve column with the following decreasing mesh apertures: 1000, 710, 500, 250, 100, 50 ⁇ and sieve bottom.
• the average diameter of the ground coated particles decreases by 2.8% compared to that of the intact coated particles.
• the coated particles prepared as described above are resistant to grinding.
• the in vitro dissolution profile of the intact coated particles prepared as described above is determined by UV spectrometry in 900 ml of 0.1 N HCl maintained at 37.0 ⁇ 0.5 ° C and stirred with a 100-rotating pallet. rpm.
• the dissolution profile obtained for the intact coated particles is shown in Table 2 below.
• Example 2 300.0 g of granules obtained in Example 1 are coated at ambient temperature in a GPCG1 fluidized air bed apparatus.
• the Wiirster equipped with a tube, with 180.6 g of polyvinylpyrrolidone (also known as povidone; Plasdone ® K29 / 32 from ISP), 90.4 g of ethylcellulose (Ethocel ® 20 premium of Dow) and 30.0 g polyethylene glycol (Super Refined PEG 400 LQ MH from Croda) dissolved in a mixture of 2070 g of acetone and 1380 g of isopropanol (60/40 m / m).
• the spraying is carried out with a flow rate of the spraying liquid of 17 g / min and lasts about 3 hours 40 minutes.
• coated particles After spraying all of the coating solution, the coated particles are recovered. Their average filming rate is about 50%. Grinding of coated particles
• coated particles prepared as described above are milled for 1 minute using an RM 200 mortar grinder from Retsch, according to the previously described protocol.
• All of the powder is recovered and sieved on a sieve column with the following decreasing mesh apertures: 1000, 710, 500, 250, 100, 50 ⁇ and sieve bottom.
• the average diameter of the ground coated particles decreases by 0.8% compared to that of the intact particles.
• coated particles prepared above are resistant to grinding.
• the in vitro dissolution profile of the intact coated particles prepared as described above is determined by UV spectrometry in 900 ml of 0.1 N HCl. held at 37.0 ⁇ 0.5 ° C and stirred by a paddle rotating at 100 rpm.
• the dissolution profile obtained is presented in the following Table 4.
• the profile thus shows an immediate release for the coated particles prepared as described above.
• Example 2 300.0 g of granules obtained in Example 1 are coated at ambient temperature in a GPCG1 fluidized air bed apparatus.
• the Wiirster equipped with a tube, with 135.0 g of hydroxypropyl methylcellulose (also known as hypromellose; Methocel ® E3 Colorcon), 135.0 g of ethyl cellulose (Ethocel ® 20 premium of Dow) and 30.0 g of polyethylene glycol (Super Refined Croda PEG 400 LQ MH) dissolved in a mixture of 3290 g of ethanol and 1410 g of water (70/30 m / m).
• the spraying is carried out with a flow rate of the spraying liquid of 20 g / min and lasts about 4 hours 15 minutes.
• the coated particles After spraying all of the coating solution, the coated particles are recovered. Their average filming rate is about 50%.
• coated particles prepared as described above are milled for 1 minute using an RM 200 mortar grinder from Retsch, according to the previously described protocol. All of the powder is recovered and sieved on a sieve column with the following decreasing mesh apertures: 1000, 710, 500, 250, 100, 50 ⁇ and sieve bottom.
• the average diameter of the ground coated particles decreases by 1.3% relative to that of the intact coated particles.
• coated particles prepared as described above are resistant to grinding.
• the in vitro dissolution profile of the intact coated particles prepared as described above is determined by UV spectrometry in 900 ml of 0.1 N HCl maintained at 37.0 ⁇ 0.5 ° C and stirred with a 100-rotating pallet. rpm.
• the dissolution profile obtained is shown in Table 6 below. TABLE 6
• Example 2 300 g of granules obtained in Example 1 are coated at ambient temperature in a GPCG1 fluidized air bed apparatus. l equipped with a Wiirster tube, with 180.2 g of a copolymer of butyl methacrylate, 2-dimethylaminoethyl methacrylate and methyl methacrylate (Eudragit ® E100 from Evonik) and 120.6 g of ethylcellulose ( Ethocel ® 20 premium of Dow), dissolved in a mixture of 2070 g of acetone and 1380 g of isopropanol (60/40 w / w). The spraying is carried out with a flow rate of the liquid to be sprayed at 21 g / min.
• a copolymer of butyl methacrylate, 2-dimethylaminoethyl methacrylate and methyl methacrylate Eudragit ® E100 from Evonik
• Ethocel ® 20 premium of Dow
• the coated particles After spraying all of the coating solution, the coated particles are recovered. Their average filming rate is about 50%.
• coated particles prepared as described above are milled for 1 minute using an RM 200 mortar grinder from Retsch, according to the previously described protocol.
• the entire powder is recovered and sieved on a sieve column with the following decreasing mesh apertures: 1000, 710, 500, 250, 100, 50 ⁇ and sieve bottom.
• 20 g of intact coated particles are sieved on a sieve column of the same mesh openings: 1000, 710, 500, 250, 100, 50 ⁇ and sieve bottom.
• the average diameter of the crushed coated particles is unchanged from that of the intact coated particles.
• coated particles prepared as described above are resistant to grinding.
• 1615.0 g of morphine sulphate and 85.0 g of polyvinylpyrrolidone (also called povidone, Plasdone K29 / 32 of ISP) are introduced with stirring into a reactor comprising 4596.3 g of water.
• the solution is heated to 75 ° C.
• the morphine sulphate crystals and the polyvinylpyrrolidone are dissolved, the solution is completely sprayed onto 300 g of cellulose spheres (Pharmatrans Cellet 90) in a GPCG1 fluidized air bed apparatus. l in a bottom spray configuration.
• the product obtained is sieved through sieves of 80 ⁇ and 250 ⁇ . 1700.4 g of granules of 80 ⁇ to 250 ⁇ (which corresponds to the fraction of product having passed through the sieves of the sieve of 250 ⁇ and retained on the sieve of 80 ⁇ ) are then recovered.
• 300.0 g of granules obtained are coated at ambient temperature in a GPCG1 fluidized air bed apparatus. l equipped with a Wiirster tube, with 57.9 g of a copolymer of butyl methacrylate, 2-dimethylaminoethyl methacrylate and methyl methacrylate (Eudragit ® E100 from Evonik), 57.9 g of ethylcellulose ( Ethocel ® 20 premium of Dow) and 12.9 g of triethyl citrate (Citrofol Al Jungbunzlauer) dissolved in a mixture of 887 g of acetone and 591 g of isopropanol (60/40 w / w). Spraying is carried out with a flow rate of the spray liquid of 21 g / min and lasts about 1 hour 30 minutes. After spraying all of the coating solution, the coated particles are recovered. Their average filming rate is about 30%.
• coated particles prepared as described above are milled for 1 minute using an RM 200 mortar grinder from Retsch, according to the previously described protocol.
• All of the powder is recovered and sieved on a sieve column with the following decreasing mesh apertures: 1000, 710, 500, 250, 100, 50 ⁇ and sieve bottom.
• the average diameter of the crushed coated particles is unchanged from that of the intact coated particles.
• coated particles prepared as described above are resistant to Dissolution profiles of intact coated particles
• the in vitro dissolution profile of the intact coated particles prepared as described above is determined by UV spectrometry in 900 mL of 0.1 N HCl held at 37.0 ⁇ 0.5 ° C and stirred with a 100-turn pallet. rpm.
• the dissolution profile obtained is presented in the following Table 10.
• the profile thus shows an immediate release for the coated particles prepared as described above.
• 400.0 g of granules obtained according to the preceding step are coated at ambient temperature in a GPCG1 fluidized air bed apparatus.
• the Wiirster equipped with a tube, with 240.0 g of polyvinylpyrrolidone (also known as povidone; Plasdone ® K29 / 32 from ISP) and 160 g of ethyl cellulose (Ethocel ® 20 premium of Dow), dissolved in a mixture of 2731 g of acetone and 1821 g of isopropanol (60/40 m / m).
• the spraying is carried out with a flow rate of the spraying liquid of 20 g / min and lasts about 4 hours 5 minutes.
• coated particles prepared as described above are milled for 1 minute using an RM 200 mortar grinder from Retsch, according to the previously described protocol.
• All of the powder is recovered and sieved on a sieve column with the following decreasing mesh apertures: 1000, 710, 500, 250, 100, 50 ⁇ and sieve bottom.
• the average diameter of the ground coated particles decreased by 3.8% compared with that of the intact coated particles.
• coated particles prepared as described above are resistant to grinding.
• the recovered powder is observed using a binocular magnifying glass of the Carl Zeiss Stemi SV11 type (magnification ⁇ 1.6) and is compared with the coated particles prepared as described above before grinding.
• coated particles prepared as described above were resistant to grinding.
• the in vitro dissolution profile of the intact coated particles prepared as described above is determined by UV spectrometry in 900 ml of 0.1 N HCl. held at 37.0 ⁇ 0.5 ° C and stirred by a paddle rotating at 100 rpm.
• the dissolution profile obtained is presented in the following Table 12.
• the profile thus shows an immediate release for the particles coated with hydromorphone hydrochloride prepared as described above.
• 400.0 g of granules obtained according to the preceding step are coated at ambient temperature in a GPCG1 fluidized air bed apparatus.
• the Wiirster equipped with a tube, with 320.0 g of polyvinylpyrrolidone (also known as povidone; Plasdone ® K29 / 32 from ISP) and 80 g of ethyl cellulose (Ethocel ® 20 premium of Dow), dissolved in a mixture of 2731 g of acetone and 1821 g of isopropanol (60/40 m / m).
• the spraying is carried out with a flow rate of the liquid to be sprayed at 20 g / min and lasts approximately 4 hours.
• the coated particles After spraying all of the coating solution, the coated particles are recovered. Their average filming rate is about 50%.
• coated particles prepared as described above are milled for 1 minute using an RM 200 mortar grinder from Retsch, according to the previously described protocol. All of the powder is recovered and sieved on a sieve column with the following decreasing mesh apertures: 1000, 710, 500, 250, 100, 50 ⁇ and sieve bottom.
• the average diameter of the crushed coated particles decreases by 16.7% compared to that of the intact coated particles.
• the coated particles prepared as described above are not resistant to grinding if we consider that the variation of the average diameter calculated is, in absolute value, less than or equal to 15%, that is to say that this variation is at the same scale as that verified for the particles illustrated in Examples 1 to 6 above.
• the coated particles prepared as described above are resistant to grinding.
• the particles prepared according to Example 7 have a grind resistance lower than that of the particles according to Examples 1 to 6, this resistance remaining nevertheless acceptable for the anti-misuse properties expected according to the invention.
• the in vitro dissolution profile of the intact particles prepared as described above is determined by UV spectrometry in 900 ml of 0.1 N HCl maintained at 37.0 ⁇ 0.5 ° C and stirred with a paddle rotating at 100 rpm. .
• the dissolution profile obtained is shown in the following Table 14.
• 380.0 g of granules obtained according to the preceding step are coated at ambient temperature in a GPCG1 fluidized air bed apparatus.
• the Wiirster equipped with a tube, with 133.0 g of hydroxypropyl cellulose (Klucel EF Hercules Aqualon) and 247.0 g of ethyl cellulose (Ethocel ® 20 premium of Dow), dissolved in a mixture of 2235 g of acetone, 1557 g of isopropanol and 432 g of water (53/37/10 m / m).
• the spraying is carried out with a flow rate of the liquid to be sprayed at 20 g / min.
• the coated particles are screened on a screen of 200 ⁇ .
• the coated particles, greater than 200 ⁇ are recovered. Their average filming rate is about 50%.
• coated particles prepared as described above are milled for 1 minute using an RM 200 mortar grinder from Retsch, according to the previously described protocol. All of the powder is recovered and sieved on a sieve column with the following decreasing mesh apertures: 1000, 710, 500, 250, 100, 50 ⁇ and sieve bottom.
• the average diameter of the ground coated particles decreases by 1.6% relative to that of the intact coated particles.
• coated particles prepared as described above are resistant to grinding.
• the profile thus shows a prolonged release for the particles coated with hydromorphone hydrochloride prepared as described above, which release does not conform to the invention.
• step 1 300.0 g of granules obtained according to Example 6 (step 1) are coated at ambient temperature in a GPCG1 fluidized air bed apparatus.
• the Wiirster equipped with a tube, with 150.0 g of polyvinylpyrrolidone (also known as povidone; Plasdone ® K29 / 32 from ISP), 120.0 g ammonio methacrylate copolymer (Eudragit ® RL 100 Evonik) and 30.0 g of triethyl citrate (Jungbunzlauer Citrofol AI), dissolved in a mixture of 2070 g of acetone and 1380 g of isopropanol (60/40 m / m).
• the spraying is carried out with a flow rate of the liquid to be sprayed at 20 g / min and lasts approximately 3 hours 30 minutes.
• coated particles After spraying all of the coating solution, the coated particles are recovered. Their average filming rate is about 50%. Grinding of coated particles
• coated particles prepared as described above are milled for 1 minute using an RM 200 mortar grinder from Retsch, according to the previously described protocol.
• All of the powder is recovered and sieved on a sieve column with the following decreasing mesh apertures: 1000, 710, 500, 250, 100, 50 ⁇ and sieve bottom.
• the average diameter of the ground coated particles is 5.8% lower than that of the intact coated particles.
• coated particles prepared as described above are resistant to grinding.
• the in vitro dissolution profile of the intact coated particles prepared as described above is determined by UV spectrometry in 900 ml of 0.1 N HCl. held at 37.0 ⁇ 0.5 ° C and stirred by a paddle rotating at 100 rpm.
• the dissolution profile obtained is presented in the following Table 18.
• step 2 175.0 g of hydromorphone hydrochloride-coated microparticles prepared according to Example 6 (step 2) and 23.0 g of polyoxyethylene (Dow's Sentry Polyox® WSR 303 NF-LEO) are mixed for 15 minutes using an automatic mixer of Rouen wheel type. 2.0 g of magnesium stearate are then added. The mixture is again homogenized for 15 minutes using the automatic mixer of Rouen Wheel type.
• step 2 175.0 g of hydromorphone hydrochloride-coated microparticles prepared according to Example 6 (step 2) and 23.0 g of polyoxyethylene (Dow's Sentry Polyox® WSR 303 NF-LEO) are mixed for 15 minutes using an automatic mixer of Rouen wheel type. 2.0 g of magnesium stearate are then added. The mixture is again homogenized for 15 minutes using the automatic mixer of Rouen Wheel type.
• the mixture is divided into size 3 gelatin capsules at the rate of about 175 mg of the mixture, ie 16 mg of hydromorphone hydrochloride.
• the in vitro dissolution profile of the capsules prepared as described above is determined by UV spectrometry in 900 mL of 0.1N HCl maintained at 37.0 ⁇ 0.5 ° C and stirred by a paddle rotating at 100 rpm.
• the dissolution profile obtained is presented in the following Table 19. TABLE 19
• the contents of a capsule prepared as described above is milled for 1 minute using a 250 ml Pyrex mortar and the corresponding pyrex pestle. 10 ml of tap water are poured into the mortar containing the ground powder. The dispersion is stirred with a magnetic stirrer and a magnetic bar (2.5 cm long) for 10 minutes at room temperature.
• the dispersion obtained is observed: it has the appearance of a heterogeneous and viscous liquid.
• the dispersion obtained is then withdrawn for 5 minutes using a 10 ml syringe provided with a 27G needle whose tip is covered with a cotton pellet.
• the amount of liquid withdrawn into the syringe is about 0.2 ml, corresponding to about 2% of the volume of extraction solvent introduced.
• capsules prepared as described above are in accordance with the invention.
• capsules 175.0 g of hydromorphone hydrochloride coated microparticles prepared according to Example 7 and 23.0 g of polyoxyethylene (Dow's Sentry Polyox® WSR 303 NF-LEO) are mixed for 15 minutes using a mixer. Automatic type Röhn wheel. 2.0 g of magnesium stearate are then added. The mixture is again homogenized for 15 minutes using the automatic mixer of Rouen Wheel type.
• the mixture is divided into size 3 gelatin capsules at a rate of about 174 mg of the mixture, ie 16 mg of hydromorphone hydrochloride.
• the in vitro dissolution profile of the capsules prepared as described above is determined by UV spectrometry in 900 ml of 0.1 N HCl held at 37.0 ⁇ 0.5 ° C. and stirred with a paddle rotating at 100 rpm.
• the dissolution profile obtained is presented in the following Table 21.
• hydromorphone hydrochloride capsules prepared as described above are in accordance with the invention.
• step 2 Preparation of tablets 74.5 g of hydromorphone hydrochloride-coated microparticles prepared according to Example 6 (step 2) are mixed with 9.6 g of polyoxyethylene (Dow Sentry Polyox® WSR 303 F-LEO), 50.4 g of cellulose. microcrystalline (Avicel® PH 101 from FMC), 62.6 g of mannitol (Pearlitol® SD 200 from Roquette), 1.0 g of anhydrous colloidal silica (Aerosil® 200) and 2.0 g of magnesium stearate.
• This mixture is used for the manufacture of round tablets with a diameter of 10 mm of 415 mg, corresponding to 16 mg of hydromorphone hydrochloride, thanks to a Korsch XP1 press.
• the compressive force applied to the mixture is 35 kN.
• the tablets thus produced have a hardness of about 86 N.
• the in vitro dissolution profile of the tablets prepared as described above is determined by UV spectrometry in 900 mL of 0.1 N HCI maintained at 37.0 ⁇ 0.5 ° C and stirred by a paddle rotating at 100 rpm.
• the dissolution profile obtained is presented in the following Table 23.
• the profile thus shows immediate release for hydromorphone hydrochloride tablets prepared as described above.
• a tablet prepared as described above is milled for 1 minute using a 250 ml Pyrex mortar and the corresponding pyrex pestle. 10 ml of tap water are poured into the mortar containing the ground powder. The dispersion is agitated at using a magnetic stirrer and a magnetic bar (2.5 cm long) for 10 minutes at room temperature.
• the dispersion obtained is observed: it has the appearance of a heterogeneous and viscous liquid.
• the dispersion obtained is then withdrawn for 5 minutes using a 10 ml syringe provided with a 27G needle whose tip is covered with a cotton pellet.
• the amount of liquid withdrawn into the syringe is less than 0.1 ml, corresponding to less than 1% of the volume of extraction solvent introduced.
• hydromorphone hydrochloride tablets prepared as described above are in accordance with the invention.
• step 2 141.4 g of microparticles coated with oxycodone hydrochloride prepared according to Example 4 (step 2), 7.1 g of polyoxyethylene (Dow Sentry Polyox® WSR 303 F-LEO), 35.4 g of hydroxypropyl cellulose (Klucel® HF Aqualon-Hercules), 14.1 g xanthan gum (Xantural® 180 from CP Kelco) are mixed for 15 minutes using an automatic mixer type Röhn Wheel. 2.1 g of magnesium stearate are added. The mixture is again homogenized for 15 minutes using the automatic mixer of Rouen Wheel type.
• step 2 141.4 g of microparticles coated with oxycodone hydrochloride prepared according to Example 4 (step 2), 7.1 g of polyoxyethylene (Dow Sentry Polyox® WSR 303 F-LEO), 35.4 g of hydroxypropyl cellulose (Klucel® HF Aqualon-Hercules), 14.1 g xanthan gum (Xant
• the mixture is distributed in size 3 gelatin capsules are filled by the above mixture, at a rate of 141 mg of mixture, or 40 mg of oxycodone hydrochloride.
• the in vitro dissolution profile of the capsules prepared as described above is determined by UV spectrometry in 900 ml of 0.1 N HCI maintained at 37.0 ⁇ 0.5. ° C and stirred by a paddle rotating at 100 rpm.
• the dissolution profile obtained is presented in the following Table 24.
• the contents of a capsule prepared as described above is milled for 1 minute using a 250 ml Pyrex mortar and the corresponding pyrex pestle. 10 ml of tap water are poured into the mortar containing the ground powder. The dispersion is stirred with a magnetic stirrer and a magnetic bar (2.5 cm long) for 10 minutes at room temperature.
• the dispersion obtained is observed: it has the appearance of a heterogeneous and viscous liquid.
• the dispersion obtained is then withdrawn for 5 minutes using a 10 ml syringe provided with a 27G needle whose tip is covered with a cotton pellet.
• the amount of liquid withdrawn into the syringe is about 0.3 ml, corresponding to about 3% of the volume of extraction solvent introduced.
• step 1 300.0 g of morphine sulfate granules prepared in Example 5 (step 1) are coated at room temperature, in a GPCG1.1 fluidized air bed apparatus, with 300.2 g of polyvinylpyrrolidone having a molar mass of about 1 000 000 g / mol (Kollidon ® 90F from BASF), dissolved in a mixture of 2070 g of acetone and 1380 g of isopropanol (60/40 m / m).
• the target filming rate is 50%.
• the spraying is carried out with a flow rate of the spraying liquid of 7 g / min and lasts approximately 8 hours 15 minutes.
• the coating solution comprising the polyvinylpyrrolidone of molar mass of about 1,000,000 g / mol
• the flow rate of the liquid to be sprayed will be increased.
• the spraying time will not be decreased since the amount of spray solution has been increased.
• the amounts of organic solvents used are very important.
• Example 4 400.0 g of oxycodone hydrochloride granules obtained in Example 1 are coated at room temperature, in a GPCG1.1 fluidized air bed apparatus equipped with a Wiirster tube, with 360.0 g of polyvinylpyrrolidone (also named povidone; Plasdone ® K29 / 32 from ISP) and 40.0 g of polyethylene glycol (PEG 400 Super Refined LQ MH Croda) dissolved in a mixture of 2760 g of acetone and 1840 g of isopropanol (60/40 m / m). The spraying is carried out with a flow rate of the liquid to be sprayed at 20 g / min.
• polyvinylpyrrolidone also named povidone; Plasdone ® K29 / 32 from ISP
• PEG 400 Super Refined LQ MH Croda polyethylene glycol
• the coated particles After spraying all of the coating solution, the coated particles are recovered. Their average filming rate is about 50%.
• the recovered product is observed using a binocular magnifying glass of the Carl Zeiss Stemi SV 11 type (magnification ⁇ 1.6): the recovered product has the appearance of quasi-particles. spherical cream colored, distinct from each other and with diameters observed around 200 ⁇ .
• coated particles prepared as described above corresponding to a dose of 80 mg of oxycodone hydrochloride, are ground manually in a 250 ml Pyrex mortar and with the pestle also corresponding Pyrex, for 50 turns (45 seconds).
• the recovered powder is observed using a binocular magnifying glass of the type Carl Zeiss Stemi SV 11 (magnification ⁇ 1.6). The observations show a majority of fine white powder consisting of fine crystals, transparent coating breaks and particles identified as cellulose spheres.
• Coating step 400.0 g of granules obtained according to the preceding step are coated at ambient temperature in a GPCG1 fluidized air bed apparatus.
• the Wiirster equipped with a tube with 80.0 g of polyvinylpyrrolidone (also known as povidone; Plasdone ® K29 / 32 from ISP) and 53.3 g of ethylcellulose (Ethocel ® 20 premium of Dow), dissolved in a mixture 920.0 g of acetone and 613.3 g of isopropanol (60/40 m / m).
• the spraying is carried out with an average flow rate of the liquid to be sprayed at 20.5 g / min.
• coated particles After spraying all of the coating solution, the coated particles are recovered. Their average filming rate is about 25%. Grinding of coated particles
• coated particles prepared as described above are milled for 1 minute using an RM 200 mortar grinder from Retsch, according to the previously described protocol.
• All of the powder is recovered and sieved on a sieve column with the following decreasing mesh apertures: 1000, 710, 500, 250, 100, 50 ⁇ and sieve bottom.
• the average diameter of the ground coated particles decreased by 23% compared to that of the intact coated particles.
• coated particles prepared as described above are not resistant to grinding.
• the in vitro dissolution profile of the intact coated particles prepared as described above is determined by UV spectrometry in 900 ml of 0.1 N HCl maintained at 37.0 ⁇ 0.5 ° C and stirred with a 100-rotating pallet. rpm.
• the dissolution profile obtained is presented in the following Table 27.
• the profile thus shows an immediate release for the particles coated with hydromorphone hydrochloride prepared as described above.

Landscapes

• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Emergency Medicine (AREA)
• Nutrition Science (AREA)
• Physiology (AREA)
• Neurosurgery (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Pain & Pain Management (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=48170593

Family Applications (1)

Country Status (10)

Families Citing this family (21)

Family Cites Families (11)

• 2012
  • 2012-12-13 FR FR1261991A patent/FR2999426B1/fr not_active Expired - Fee Related
• 2013
  • 2013-12-12 CA CA2894647A patent/CA2894647A1/fr not_active Abandoned
  • 2013-12-12 AU AU2013356872A patent/AU2013356872B2/en not_active Ceased
  • 2013-12-12 US US14/651,468 patent/US20150328168A1/en not_active Abandoned
  • 2013-12-12 EP EP13824380.3A patent/EP2931278A1/de not_active Withdrawn
  • 2013-12-12 KR KR1020157018627A patent/KR20150094750A/ko not_active Application Discontinuation
  • 2013-12-12 JP JP2015547241A patent/JP2016503002A/ja not_active Ceased
  • 2013-12-12 WO PCT/IB2013/060843 patent/WO2014091437A1/fr active Application Filing
• 2015
  • 2015-06-10 IL IL239325A patent/IL239325A0/en unknown
  • 2015-07-06 ZA ZA2015/04855A patent/ZA201504855B/en unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events